Complete disappearance of pulmonary metastases in a case of hepatocellular carcinoma treated with docetaxel-based systemic chemotherapy

被引:10
作者
Ishikawa, T
Ichida, T
Yokoyama, J
Matsuda, Y
Watanabe, T
Asakura, H
机构
[1] Niigata Univ, Sch Med, Dept Internal Med 3, Niigata 9518122, Japan
[2] Saiseikai Sanjo Hosp, Div Gastroenterol & Hepatol, Niigata, Japan
关键词
docetaxel; hepatocellular carcinoma; lung metastasis;
D O I
10.1111/j.1440-1746.2004.03737.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
A case of the complete shrinkage of pulmonary metastases from multiple hepatocellular carcinomas (HCC) after administration of docetaxel, cisplatin and enteric-coated tegafur/uracil is reported. A 54-year-old Japanese man was diagnosed with recurrent multiple HCC associated with pulmonary metastases and compensated liver cirrhosis. Docetaxel, cisplatin and enteric-coated tegafur/uracil were given to this patient. After 2 months of treatment, there was a decrease in tumor markers and a shrinkage of the pulmonary metastases. Image analyses such as chest X-rays and chest computed tomography scans showed a disappearance of the pulmonary metastases, although the multiple HCC did not disappear completely. This was evaluated as a complete remission of metastatic lesions or a partial remission of primary lesions according to the World Health Organization criteria. No recurrence of pulmonary metastasis was seen for 10 months. This combination therapy was well-tolerated for lung cancer and could represent an effective treatment for pulmonary metastases from HCC. (C) 2004 Blackwell Publishing Asia Pty Ltd.
引用
收藏
页码:1423 / 1426
页数:4
相关论文
共 22 条
[1]  
Belani C, 2001, SEMIN ONCOL, V28, P10, DOI [10.1053/sonc.2001.24602, 10.1053/sonc.20901.18403]
[2]   Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer [J].
Bruno, R ;
Hille, D ;
Riva, A ;
Vivier, N ;
Huinnink, WWTB ;
van Oosterom, AT ;
Kaye, SB ;
Verweij, J ;
Fossella, FV ;
Valero, V ;
Rigas, JR ;
Seidman, AD ;
Chevallier, B ;
Fumoleau, P ;
Burris, HA ;
Ravclin, PM ;
Sheiner, LB .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :187-196
[3]   DOCETAXEL [J].
CORTES, JE ;
PAZDUR, R .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) :2643-2655
[4]  
Ichida T, 1996, HEPATO-GASTROENTEROL, V43, P1575
[5]  
Ishikawa T, 1999, AM J GASTROENTEROL, V94, P1682, DOI 10.1111/j.1572-0241.1999.01163.x
[6]   Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma [J].
Ishikawa, T ;
Ichida, T ;
Sugitani, S ;
Tsuboi, Y ;
Genda, T ;
Sugahara, S ;
Uehara, K ;
Inayoshi, J ;
Yokoyama, J ;
Ishimoto, Y ;
Asakura, H .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (04) :452-459
[7]   Extrahepatic metastases of hepatocellular carcinoma [J].
Katyal, S ;
Oliver, JH ;
Peterson, MS ;
Ferris, JV ;
Carr, BS ;
Baron, RL .
RADIOLOGY, 2000, 216 (03) :698-703
[8]  
Lin HL, 2000, CANCER-AM CANCER SOC, V89, P983, DOI 10.1002/1097-0142(20000901)89:5<983::AID-CNCR7>3.0.CO
[9]  
2-G
[10]  
*LIV CANC STUD GRO, 2000, ACTA HEPATOL JAP, V41, P799